Becton Dickinson & Co. (NYSE:BDX) said this week that its second-generation BD Nano pen needle won 510(k) clearance from the FDA.
The company’s needles are designed to provide a more reliable subcutaneous injection depth, according to BD.
Using a contoured needle base and distributed pressure, the pen needle lessens the risk resulting from user injection force variability. The new design contributed an 8-fold reduction in calculated intramuscular injection risk, BD reported.
The company also touted the pen’s ergonomic design, saying that it makes the device easier to use and provides a more comfortable injection experience.
“The launch of BD Nano 2nd gen pen needles reinforces BD’s commitment to providing the most advanced solutions possible for people with diabetes to help achieve better clinical management of insulin use,” Dr. Stanislav Glezer, global VP of medical affairs, said in prepared remarks.
“In addition to the added clinical benefits the latest BD innovation brings, the new ergonomic pen needle features can help people feel more comfortable with their injection experience,” Glezer added.
